Nidek adds low vision feedback exam to MP-3

Nidek Co. announced the launch of the feedback exam for visual rehabilitation and scotopic microperimetry for the MP-3 Microperimeter.

The MP-3 measures and displays the local retinal sensitivity for functional assessment of the retina. The feedback exam function provides visual rehabilitation training for patients who have lost foveal fixation, helping them relocate their preferred retinal locus to a different region, the trained retinal locus.

The feedback exam is released as a standard function in the MP-3.

The MP-3 type S, which provides scotopic microperimetry and is used to assess the changes in rod sensitivity of degenerative retinal diseases, is being released concurrently. This modality can be used in clinical trials of new therapeutics for retinal diseases that impair rod function.

The MP-3 type S is currently available only in countries with CE marking; these features of the MP-3 are not yet approved by the FDA for distribution in the U.S.

Motoki Ozawa, president and CEO of Nidek, said in the release, “The incorporation of these new functions in the MP-3 will allow low vision care providers to offer enhanced options for low vision patients.”

Nidek Co. announced the launch of the feedback exam for visual rehabilitation and scotopic microperimetry for the MP-3 Microperimeter.

The MP-3 measures and displays the local retinal sensitivity for functional assessment of the retina. The feedback exam function provides visual rehabilitation training for patients who have lost foveal fixation, helping them relocate their preferred retinal locus to a different region, the trained retinal locus.

The feedback exam is released as a standard function in the MP-3.

The MP-3 type S, which provides scotopic microperimetry and is used to assess the changes in rod sensitivity of degenerative retinal diseases, is being released concurrently. This modality can be used in clinical trials of new therapeutics for retinal diseases that impair rod function.

The MP-3 type S is currently available only in countries with CE marking; these features of the MP-3 are not yet approved by the FDA for distribution in the U.S.

Motoki Ozawa, president and CEO of Nidek, said in the release, “The incorporation of these new functions in the MP-3 will allow low vision care providers to offer enhanced options for low vision patients.”